{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:35:14Z","timestamp":1791689714219,"version":"4.3.4"},"reference-count":240,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273012"],"award-info":[{"award-number":["82273012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472674"],"award-info":[{"award-number":["82472674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"1\u00b73\u00b75 project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYYC22003"],"award-info":[{"award-number":["ZYYC22003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brain metastases (BMs) are the most common intracranial tumors in adults and the major cause of cancer-related morbidity and mortality. The occurrence of BMs varies according to the type of primary tumors with most frequence in lung cancer, melanoma and breast cancer. Among of them, lung cancer has been reported to have a higher risk of BMs than other types of cancers with 40\u2009~\u200950% of such patients will develop BMs during the course of disease. BMs lead to many neurological complications and result in a poor quality of life and short life span. Although the treatment strategies were improved for brain tumors in the past decades, the prognosis of BMs patients is grim. Poorly understanding of the molecular and cellular characteristics of BMs and the complicated interaction with brain microenvironment are the major reasons for the dismal prognosis of BM patients. Recent studies have enhanced understanding of the mechanisms of BMs. The newly identified potential therapeutic targets and the advanced therapeutic strategies have brought light for a better cure of BMs. In this review, we summarized the mechanisms of BMs during the metastatic course, the molecular and cellular landscapes of BMs, and the advances of novel drug delivery systems for overcoming the obstruction of blood\u2013brain barrier (BBB). We further discussed the challenges of the emerging therapeutic strategies, such as synergistic approach of combining targeted therapy with immunotherapy, which will provide vital clues for realizing the precise and personalized medicine for BM patients in the future.<\/jats:p>","DOI":"10.1186\/s43556-025-00251-0","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:16:42Z","timestamp":1740475002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cancer brain metastasis: molecular mechanisms and therapeutic strategies"],"prefix":"10.1186","volume":"6","author":[{"given":"Yu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0730-6291","authenticated-orcid":false,"given":"Liguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"251_CR1","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1158\/0008-5472.CAN-08-4347","volume":"69","author":"EA Maher","year":"2009","unstructured":"Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Res. 2009;69:6015\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4347.","journal-title":"Cancer Res"},{"key":"251_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y.","journal-title":"Curr Oncol Rep"},{"key":"251_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y.","journal-title":"Nat Rev Dis Primers"},{"key":"251_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829.","journal-title":"Contemp Oncol (Pozn)"},{"key":"251_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2018.12.009","volume":"129","author":"N Andratschke","year":"2019","unstructured":"Andratschke N, Kraft J, Nieder C, Tay R, Califano R, Soffietti R, et al. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer. 2019;129:63\u201371. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.009.","journal-title":"Lung Cancer"},{"key":"251_CR6","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.2147\/IJGM.S342009","volume":"14","author":"N Li","year":"2021","unstructured":"Li N, Chu Y, Song Q. Brain metastasis in patients with small cell lung cancer. Int J Gen Med. 2021;14:10131\u20139. https:\/\/doi.org\/10.2147\/IJGM.S342009.","journal-title":"Int J Gen Med"},{"key":"251_CR7","doi-asserted-by":"publisher","first-page":"166557","DOI":"10.1016\/j.bbadis.2022.166557","volume":"1868","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166557. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166557.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"251_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13402-017-0345-5","volume":"40","author":"M Yousefi","year":"2017","unstructured":"Yousefi M, Bahrami T, Salmaninejad A, Nosrati R, Ghaffari P, Ghaffari SH. Lung cancer-associated brain metastasis: molecular mechanisms and therapeutic options. Cell Oncol (Dordr). 2017;40:419\u201341. https:\/\/doi.org\/10.1007\/s13402-017-0345-5.","journal-title":"Cell Oncol (Dordr)"},{"key":"251_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41419-021-04004-z","volume":"12","author":"D Wu","year":"2021","unstructured":"Wu D, Deng S, Li L, Liu T, Zhang T, Li J, et al. TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p\/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death Dis. 2021;12:721. https:\/\/doi.org\/10.1038\/s41419-021-04004-z.","journal-title":"Cell Death Dis"},{"key":"251_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12935-021-02263-6","volume":"21","author":"LY Ye","year":"2021","unstructured":"Ye LY, Sun LX, Zhong XH, Chen XS, Hu S, Xu RR, et al. The structure of blood-tumor barrier and distribution of chemotherapeutic drugs in non-small cell lung cancer brain metastases. Cancer Cell Int. 2021;21:556. https:\/\/doi.org\/10.1186\/s12935-021-02263-6.","journal-title":"Cancer Cell Int"},{"key":"251_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbcan.2016.12.001","volume":"1867","author":"FJ Lowery","year":"2017","unstructured":"Lowery FJ, Yu D. Brain metastasis: unique challenges and open opportunities. Biochim Biophys Acta Rev Cancer. 2017;1867:49\u201357. https:\/\/doi.org\/10.1016\/j.bbcan.2016.12.001.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"251_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337\u201341. https:\/\/doi.org\/10.1038\/nature14432.","journal-title":"Nature"},{"key":"251_CR13","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","volume":"33","author":"X Lin","year":"2015","unstructured":"Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33:3475\u201384. https:\/\/doi.org\/10.1200\/JCO.2015.60.9503.","journal-title":"J Clin Oncol"},{"key":"251_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fonc.2018.00161","volume":"8","author":"F Franchino","year":"2018","unstructured":"Franchino F, Ruda R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161. https:\/\/doi.org\/10.3389\/fonc.2018.00161.","journal-title":"Front Oncol"},{"key":"251_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17:279\u201399. https:\/\/doi.org\/10.1038\/s41571-019-0320-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"251_CR16","doi-asserted-by":"publisher","first-page":"S256","DOI":"10.4103\/2152-7806.111303","volume":"4","author":"R Ramakrishna","year":"2013","unstructured":"Ramakrishna R, Rostomily R. Seed, soil, and beyond: the basic biology of brain metastasis. Surg Neurol Int. 2013;4:S256-64. https:\/\/doi.org\/10.4103\/2152-7806.111303.","journal-title":"Surg Neurol Int"},{"key":"251_CR17","doi-asserted-by":"publisher","first-page":"e108647","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40:e108647. https:\/\/doi.org\/10.15252\/embj.2021108647.","journal-title":"EMBO J"},{"key":"251_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/0008-5472.CAN-13-1641","volume":"74","author":"A Fantozzi","year":"2014","unstructured":"Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, et al. VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res. 2014;74:1566\u201375. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1641.","journal-title":"Cancer Res"},{"key":"251_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","volume":"25","author":"X Ye","year":"2015","unstructured":"Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25:675\u201386. https:\/\/doi.org\/10.1016\/j.tcb.2015.07.012.","journal-title":"Trends Cell Biol"},{"key":"251_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463\u20138. https:\/\/doi.org\/10.1038\/s41586-018-0040-3.","journal-title":"Nature"},{"key":"251_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/CCO.0b013e32835b6371","volume":"25","author":"Y Katsuno","year":"2013","unstructured":"Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25:76\u201384. https:\/\/doi.org\/10.1097\/CCO.0b013e32835b6371.","journal-title":"Curr Opin Oncol"},{"key":"251_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97\u2013110. https:\/\/doi.org\/10.1038\/nrc3447.","journal-title":"Nat Rev Cancer"},{"key":"251_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275\u201392. https:\/\/doi.org\/10.1016\/j.cell.2011.09.024.","journal-title":"Cell"},{"key":"251_CR24","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1083\/jcb.201704053","volume":"216","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 2017;216:3799\u2013816. https:\/\/doi.org\/10.1083\/jcb.201704053.","journal-title":"J Cell Biol"},{"key":"251_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175\u201380. https:\/\/doi.org\/10.1126\/science.aaf4405.","journal-title":"Science"},{"key":"251_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396. https:\/\/doi.org\/10.1038\/nrm3758.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"251_CR27","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1177\/0271678X20951995","volume":"40","author":"PT Ronaldson","year":"2020","unstructured":"Ronaldson PT, Davis TP. Regulation of blood-brain barrier integrity by microglia in health and disease: a therapeutic opportunity. J Cereb Blood Flow Metab. 2020;40:S6\u201324. https:\/\/doi.org\/10.1177\/0271678X20951995.","journal-title":"J Cereb Blood Flow Metab"},{"key":"251_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","volume":"18","author":"PS Steeg","year":"2021","unstructured":"Steeg PS. The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021;18:696\u2013714. https:\/\/doi.org\/10.1038\/s41571-021-00529-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"251_CR29","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/onc.2012.313","volume":"32","author":"B Li","year":"2013","unstructured":"Li B, Wang C, Zhang Y, Zhao XY, Huang B, Wu PF, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene. 2013;32:2952\u201362. https:\/\/doi.org\/10.1038\/onc.2012.313.","journal-title":"Oncogene"},{"key":"251_CR30","doi-asserted-by":"publisher","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","volume":"8","author":"S Tiwary","year":"2018","unstructured":"Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH. Metastatic Brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep. 2018;8:8267. https:\/\/doi.org\/10.1038\/s41598-018-26636-6.","journal-title":"Sci Rep"},{"key":"251_CR31","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1038\/ncomms7716","volume":"6","author":"N Tominaga","year":"2015","unstructured":"Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. https:\/\/doi.org\/10.1038\/ncomms7716.","journal-title":"Nat Commun"},{"key":"251_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","volume":"16","author":"Y Kienast","year":"2010","unstructured":"Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116\u201322. https:\/\/doi.org\/10.1038\/nm.2072.","journal-title":"Nat Med"},{"key":"251_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1349-7006.2011.02195.x","volume":"103","author":"L Mathot","year":"2012","unstructured":"Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012;103:626\u201331. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02195.x.","journal-title":"Cancer Sci"},{"key":"251_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41556-018-0138-8","volume":"20","author":"EE Er","year":"2018","unstructured":"Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol. 2018;20:966\u201378. https:\/\/doi.org\/10.1038\/s41556-018-0138-8.","journal-title":"Nat Cell Biol"},{"key":"251_CR35","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ccell.2023.07.012","volume":"41","author":"Q Huang","year":"2023","unstructured":"Huang Q, Liu L, Xiao D, Huang Z, Wang W, Zhai K, et al. CD44(+) lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. Cancer Cell. 2023;41:1621-36 e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.012.","journal-title":"Cancer Cell"},{"key":"251_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-024-03015-w","volume":"43","author":"S Xia","year":"2024","unstructured":"Xia S, Duan W, Xu M, Li M, Tang M, Wei S, et al. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET. J Exp Clin Cancer Res. 2024;43:103. https:\/\/doi.org\/10.1186\/s13046-024-03015-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"251_CR37","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370. https:\/\/doi.org\/10.1007\/s00018-019-03351-7.","journal-title":"Cell Mol Life Sci"},{"key":"251_CR38","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/cells8121602","volume":"8","author":"X Li","year":"2019","unstructured":"Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The tumor vessel targeting strategy: a double-edged sword in tumor metastasis. Cells. 2019;8:1602. https:\/\/doi.org\/10.3390\/cells8121602.","journal-title":"Cells"},{"key":"251_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/cam4.105","volume":"2","author":"T Donnem","year":"2013","unstructured":"Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2013;2:427\u201336. https:\/\/doi.org\/10.1002\/cam4.105.","journal-title":"Cancer Med"},{"key":"251_CR40","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1002\/ctm2.246","volume":"10","author":"H Ruan","year":"2020","unstructured":"Ruan H, Zhou Y, Shen J, Zhai Y, Xu Y, Pi L, et al. Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis. Clin Transl Med. 2020;10:e246. https:\/\/doi.org\/10.1002\/ctm2.246.","journal-title":"Clin Transl Med"},{"key":"251_CR41","doi-asserted-by":"publisher","first-page":"14344","DOI":"10.1038\/ncomms14344","volume":"8","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, et al. Expression of beta-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun. 2017;8:14344. https:\/\/doi.org\/10.1038\/ncomms14344.","journal-title":"Nat Commun"},{"key":"251_CR42","doi-asserted-by":"publisher","first-page":"21677","DOI":"10.1073\/pnas.1016234107","volume":"107","author":"DG Duda","year":"2010","unstructured":"Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107:21677\u201382. https:\/\/doi.org\/10.1073\/pnas.1016234107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"251_CR43","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1158\/0008-5472.CAN-15-1633","volume":"75","author":"Z Ao","year":"2015","unstructured":"Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, et al. Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 2015;75:4681\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1633.","journal-title":"Cancer Res"},{"key":"251_CR44","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41467-017-00985-8","volume":"8","author":"A Glentis","year":"2017","unstructured":"Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun. 2017;8:924. https:\/\/doi.org\/10.1038\/s41467-017-00985-8.","journal-title":"Nat Commun"},{"key":"251_CR45","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.3390\/cancers13184720","volume":"13","author":"PJ Asif","year":"2021","unstructured":"Asif PJ, Longobardi C, Hahne M, Medema JP. The role of cancer-associated fibroblasts in cancer invasion and metastasis. Cancers (Basel). 2021;13:4720. https:\/\/doi.org\/10.3390\/cancers13184720.","journal-title":"Cancers (Basel)"},{"key":"251_CR46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fimmu.2018.00414","volume":"9","author":"L Ziani","year":"2018","unstructured":"Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414. https:\/\/doi.org\/10.3389\/fimmu.2018.00414.","journal-title":"Front Immunol"},{"key":"251_CR47","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","volume":"10","author":"L Monteran","year":"2019","unstructured":"Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. https:\/\/doi.org\/10.3389\/fimmu.2019.01835.","journal-title":"Front Immunol"},{"key":"251_CR48","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1126\/science.7863341","volume":"267","author":"K Karre","year":"1995","unstructured":"Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978\u20139. https:\/\/doi.org\/10.1126\/science.7863341.","journal-title":"Science"},{"key":"251_CR49","doi-asserted-by":"publisher","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","volume":"111","author":"M Labelle","year":"2014","unstructured":"Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111:E3053-61. https:\/\/doi.org\/10.1073\/pnas.1411082111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"251_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009.","journal-title":"Cancer Cell"},{"key":"251_CR51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","volume":"126","author":"AT Franco","year":"2015","unstructured":"Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582\u20138. https:\/\/doi.org\/10.1182\/blood-2014-08-531582.","journal-title":"Blood"},{"key":"251_CR52","doi-asserted-by":"publisher","first-page":"111298","DOI":"10.1016\/j.celrep.2022.111298","volume":"40","author":"T Pereira-Veiga","year":"2022","unstructured":"Pereira-Veiga T, Schneegans S, Pantel K, Wikman H. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. Cell Rep. 2022;40:111298. https:\/\/doi.org\/10.1016\/j.celrep.2022.111298.","journal-title":"Cell Rep"},{"key":"251_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12307-014-0149-3","volume":"7","author":"J Velez","year":"2014","unstructured":"Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, Lopez C, et al. Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. Cancer Microenviron. 2014;7:79\u201390. https:\/\/doi.org\/10.1007\/s12307-014-0149-3.","journal-title":"Cancer Microenviron"},{"key":"251_CR54","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s12885-019-5795-x","volume":"19","author":"TN Beck","year":"2019","unstructured":"Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, et al. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer. 2019;19:603. https:\/\/doi.org\/10.1186\/s12885-019-5795-x.","journal-title":"BMC Cancer"},{"key":"251_CR55","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553\u20137. https:\/\/doi.org\/10.1038\/s41586-019-0915-y.","journal-title":"Nature"},{"key":"251_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-017-9864-8","volume":"34","author":"AK Ciminera","year":"2017","unstructured":"Ciminera AK, Jandial R, Termini J. Metabolic advantages and vulnerabilities in brain metastases. Clin Exp Metastasis. 2017;34:401\u201310. https:\/\/doi.org\/10.1007\/s10585-017-9864-8.","journal-title":"Clin Exp Metastasis"},{"key":"251_CR57","doi-asserted-by":"publisher","first-page":"v121","DOI":"10.1093\/noajnl\/vdab121","volume":"3","author":"ES Srinivasan","year":"2021","unstructured":"Srinivasan ES, Deshpande K, Neman J, Winkler F, Khasraw M. The microenvironment of brain metastases from solid tumors. Neurooncol Adv. 2021;3:v121\u201332. https:\/\/doi.org\/10.1093\/noajnl\/vdab121.","journal-title":"Neurooncol Adv"},{"key":"251_CR58","doi-asserted-by":"publisher","first-page":"932285","DOI":"10.3389\/fonc.2022.932285","volume":"12","author":"K Onwudiwe","year":"2022","unstructured":"Onwudiwe K, Burchett AA, Datta M. Mechanical and metabolic interplay in the brain metastatic microenvironment. Front Oncol. 2022;12:932285. https:\/\/doi.org\/10.3389\/fonc.2022.932285.","journal-title":"Front Oncol"},{"key":"251_CR59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-020-02256-1","volume":"141","author":"K Fukumura","year":"2021","unstructured":"Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, et al. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol. 2021;141:303\u201321. https:\/\/doi.org\/10.1007\/s00401-020-02256-1.","journal-title":"Acta Neuropathol"},{"key":"251_CR60","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-19-1228","volume":"10","author":"B Ngo","year":"2020","unstructured":"Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, et al. Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition. Cancer Discov. 2020;10:1352\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1228.","journal-title":"Cancer Discov"},{"key":"251_CR61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-019-1576-6","volume":"573","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019;573:526\u201331. https:\/\/doi.org\/10.1038\/s41586-019-1576-6.","journal-title":"Nature"},{"key":"251_CR62","doi-asserted-by":"publisher","first-page":"109880","DOI":"10.1016\/j.celrep.2021.109880","volume":"37","author":"JH Luttman","year":"2021","unstructured":"Luttman JH, Hoj JP, Lin KH, Lin J, Gu JJ, Rouse C, et al. ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Cell Rep. 2021;37:109880. https:\/\/doi.org\/10.1016\/j.celrep.2021.109880.","journal-title":"Cell Rep"},{"key":"251_CR63","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s41467-019-10042-1","volume":"10","author":"G Cheng","year":"2019","unstructured":"Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019;10:2205. https:\/\/doi.org\/10.1038\/s41467-019-10042-1.","journal-title":"Nat Commun"},{"key":"251_CR64","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.4161\/cc.5.16.3018","volume":"5","author":"GN Naumov","year":"2006","unstructured":"Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5:1779\u201387. https:\/\/doi.org\/10.4161\/cc.5.16.3018.","journal-title":"Cell Cycle"},{"key":"251_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165:45\u201360. https:\/\/doi.org\/10.1016\/j.cell.2016.02.025.","journal-title":"Cell"},{"key":"251_CR66","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1600-0463.2008.01213.x","volume":"116","author":"CE Horak","year":"2008","unstructured":"Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. APMIS. 2008;116:586\u2013601. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.01213.x.","journal-title":"APMIS"},{"key":"251_CR67","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002\u201316. https:\/\/doi.org\/10.1016\/j.cell.2014.01.040.","journal-title":"Cell"},{"key":"251_CR68","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41467-017-00983-w","volume":"8","author":"J Berrout","year":"2017","unstructured":"Berrout J, Kyriakopoulou E, Moparthi L, Hogea AS, Berrout L, Ivan C, et al. TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nat Commun. 2017;8:947. https:\/\/doi.org\/10.1038\/s41467-017-00983-w.","journal-title":"Nat Commun"},{"key":"251_CR69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature18268","volume":"533","author":"Q Chen","year":"2016","unstructured":"Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493\u20138. https:\/\/doi.org\/10.1038\/nature18268.","journal-title":"Nature"},{"key":"251_CR70","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","volume":"24","author":"N Priego","year":"2018","unstructured":"Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1024\u201335. https:\/\/doi.org\/10.1038\/s41591-018-0044-4.","journal-title":"Nat Med"},{"key":"251_CR71","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41591-022-01749-8","volume":"28","author":"C Monteiro","year":"2022","unstructured":"Monteiro C, Miarka L, Perea-Garcia M, Priego N, Garcia-Gomez P, Alvaro-Espinosa L, et al. Stratification of radiosensitive brain metastases based on an actionable S100A9\/RAGE resistance mechanism. Nat Med. 2022;28:752\u201365. https:\/\/doi.org\/10.1038\/s41591-022-01749-8.","journal-title":"Nat Med"},{"key":"251_CR72","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41556-023-01241-6","volume":"25","author":"F Qu","year":"2023","unstructured":"Qu F, Brough SC, Michno W, Madubata CJ, Hartmann GG, Puno A, et al. Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nat Cell Biol. 2023;25:1506\u201319. https:\/\/doi.org\/10.1038\/s41556-023-01241-6.","journal-title":"Nat Cell Biol"},{"key":"251_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.devcel.2024.01.010","volume":"59","author":"K Ishibashi","year":"2024","unstructured":"Ishibashi K, Ichinose T, Kadokawa R, Mizutani R, Iwabuchi S, Togi S, et al. Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Dev Cell. 2024;59:579-94 e6. https:\/\/doi.org\/10.1016\/j.devcel.2024.01.010.","journal-title":"Dev Cell"},{"key":"251_CR74","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cell.2020.09.064","volume":"183","author":"IH Guldner","year":"2020","unstructured":"Guldner IH, Wang Q, Yang L, Golomb SM, Zhao Z, Lopez JA, et al. CNS-native myeloid cells drive immune suppression in the brain metastatic niche through Cxcl10. Cell. 2020;183:1234-48 e25. https:\/\/doi.org\/10.1016\/j.cell.2020.09.064.","journal-title":"Cell"},{"key":"251_CR75","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ccell.2023.12.018","volume":"42","author":"L Bejarano","year":"2024","unstructured":"Bejarano L, Kauzlaric A, Lamprou E, Lourenco J, Fournier N, Ballabio M, et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. Cancer Cell. 2024;42:378-95 e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.018.","journal-title":"Cancer Cell"},{"key":"251_CR76","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.xcrm.2024.101533","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang L, Li C, Zhan H, Li S, Zeng K, Xu C, et al. Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. Cell Rep Med. 2024;5:101533. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101533.","journal-title":"Cell Rep Med"},{"key":"251_CR77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fonc.2018.00208","volume":"8","author":"WJ Kelly","year":"2018","unstructured":"Kelly WJ, Shah NJ, Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol. 2018;8:208. https:\/\/doi.org\/10.3389\/fonc.2018.00208.","journal-title":"Front Oncol"},{"key":"251_CR78","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3904\/kjim.2015.158","volume":"33","author":"MY Baek","year":"2018","unstructured":"Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2018;33:168\u201375. https:\/\/doi.org\/10.3904\/kjim.2015.158.","journal-title":"Korean J Intern Med"},{"key":"251_CR79","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","volume":"52","author":"DJH Shih","year":"2020","unstructured":"Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371\u20137. https:\/\/doi.org\/10.1038\/s41588-020-0592-7.","journal-title":"Nat Genet"},{"key":"251_CR80","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","volume":"14","author":"A Skakodub","year":"2023","unstructured":"Skakodub A, Walch H, Tringale KR, Eichholz J, Imber BS, Vasudevan HN, et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023;14:4980. https:\/\/doi.org\/10.1038\/s41467-023-40793-x.","journal-title":"Nat Commun"},{"key":"251_CR81","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ctrv.2007.01.006","volume":"33","author":"B Fischer","year":"2007","unstructured":"Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev. 2007;33:391\u2013406. https:\/\/doi.org\/10.1016\/j.ctrv.2007.01.006.","journal-title":"Cancer Treat Rev"},{"key":"251_CR82","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3892\/ol.2018.7859","volume":"15","author":"Y Ma","year":"2018","unstructured":"Ma Y, Chen K, Yang Z, Guan M. Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases. Oncol Lett. 2018;15:4503\u201310. https:\/\/doi.org\/10.3892\/ol.2018.7859.","journal-title":"Oncol Lett"},{"key":"251_CR83","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1002\/cncr.32372","volume":"125","author":"H Wang","year":"2019","unstructured":"Wang H, Ou Q, Li D, Qin T, Bao H, Hou X, et al. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer. 2019;125:3535\u201344. https:\/\/doi.org\/10.1002\/cncr.32372.","journal-title":"Cancer"},{"key":"251_CR84","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11864-021-00911-7","volume":"22","author":"A Pellerino","year":"2021","unstructured":"Pellerino A, Bruno F, Ruda R, Soffietti R. Systemic therapy for lung cancer brain metastases. Curr Treat Options Oncol. 2021;22:110. https:\/\/doi.org\/10.1007\/s11864-021-00911-7.","journal-title":"Curr Treat Options Oncol"},{"key":"251_CR85","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu YL, Hirsh V, O\u2019Byrne K, Yamamoto N, Mok T, et al. First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380\u201390. https:\/\/doi.org\/10.1016\/j.jtho.2015.11.014.","journal-title":"J Thorac Oncol"},{"key":"251_CR86","doi-asserted-by":"publisher","unstructured":"Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;2017. https:\/\/doi.org\/10.1200\/PO.17.00063.","DOI":"10.1200\/PO.17.00063"},{"key":"251_CR87","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017;19:i1\u201324. https:\/\/doi.org\/10.1093\/neuonc\/now197.","journal-title":"Neuro Oncol"},{"key":"251_CR88","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","volume":"13","author":"A Drilon","year":"2018","unstructured":"Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13:1595\u2013601. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.004.","journal-title":"J Thorac Oncol"},{"key":"251_CR89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrg2521","volume":"10","author":"TR Mercer","year":"2009","unstructured":"Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155\u20139. https:\/\/doi.org\/10.1038\/nrg2521.","journal-title":"Nat Rev Genet"},{"key":"251_CR90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cancergen.2017.06.003","volume":"216\u2013217","author":"W Sun","year":"2017","unstructured":"Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer Genet. 2017;216\u2013217:105\u201310. https:\/\/doi.org\/10.1016\/j.cancergen.2017.06.003.","journal-title":"Cancer Genet"},{"key":"251_CR91","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4161\/rna.24604","volume":"10","author":"L Ma","year":"2013","unstructured":"Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10:925\u201333. https:\/\/doi.org\/10.4161\/rna.24604.","journal-title":"RNA Biol"},{"key":"251_CR92","doi-asserted-by":"publisher","first-page":"e109347","DOI":"10.1371\/journal.pone.0109347","volume":"9","author":"M Liu","year":"2014","unstructured":"Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS ONE. 2014;9:e109347. https:\/\/doi.org\/10.1371\/journal.pone.0109347.","journal-title":"PLoS ONE"},{"key":"251_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11010-016-2822-y","volume":"423","author":"FF Wang","year":"2016","unstructured":"Wang FF, Wang S, Xue WH, Cheng JL. microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9. Mol Cell Biochem. 2016;423:29\u201337. https:\/\/doi.org\/10.1007\/s11010-016-2822-y.","journal-title":"Mol Cell Biochem"},{"key":"251_CR94","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.prp.2017.06.012","volume":"213","author":"LJ Chen","year":"2017","unstructured":"Chen LJ, Li XY, Zhao YQ, Liu WJ, Wu HJ, Liu J, et al. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017;213:882\u20138. https:\/\/doi.org\/10.1016\/j.prp.2017.06.012.","journal-title":"Pathol Res Pract"},{"key":"251_CR95","doi-asserted-by":"publisher","first-page":"27461","DOI":"10.18632\/oncotarget.4742","volume":"6","author":"M Singh","year":"2015","unstructured":"Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 2015;6:27461\u201377. https:\/\/doi.org\/10.18632\/oncotarget.4742.","journal-title":"Oncotarget"},{"key":"251_CR96","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.celrep.2016.04.018","volume":"15","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Joyce CE, Buquicchio F, Brown A, Ritz J, Distel RJ, et al. The lncRNA SLNCR1 mediates melanoma invasion through a conserved SRA1-like region. Cell Rep. 2016;15:2025\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.018.","journal-title":"Cell Rep"},{"key":"251_CR97","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-014-1613-0","volume":"121","author":"L Shen","year":"2015","unstructured":"Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121:101\u20138. https:\/\/doi.org\/10.1007\/s11060-014-1613-0.","journal-title":"J Neurooncol"},{"key":"251_CR98","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1172\/JCI91553","volume":"127","author":"S Wang","year":"2017","unstructured":"Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127:4498\u2013515. https:\/\/doi.org\/10.1172\/JCI91553.","journal-title":"J Clin Invest"},{"key":"251_CR99","doi-asserted-by":"publisher","first-page":"e2200230119","DOI":"10.1073\/pnas.2200230119","volume":"119","author":"W Liu","year":"2022","unstructured":"Liu W, Sun P, Xia L, He X, Xia Z, Huang Y, et al. A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain. Proc Natl Acad Sci U S A. 2022;119:e2200230119. https:\/\/doi.org\/10.1073\/pnas.2200230119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"251_CR100","doi-asserted-by":"publisher","first-page":"551","DOI":"10.18388\/abp.2020_6501","volume":"70","author":"J Zhong","year":"2023","unstructured":"Zhong J, Wang B. Long noncoding RNA LGALS8-AS1 promotes angiogenesis and brain metastases in non-small cell lung cancer. Acta Biochim Pol. 2023;70:551\u20139. https:\/\/doi.org\/10.18388\/abp.2020_6501.","journal-title":"Acta Biochim Pol"},{"key":"251_CR101","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","volume":"616","author":"C Martinez-Ruiz","year":"2023","unstructured":"Martinez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616:543\u201352. https:\/\/doi.org\/10.1038\/s41586-023-05706-4.","journal-title":"Nature"},{"key":"251_CR102","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-021-00151-w","volume":"5","author":"T Jiang","year":"2021","unstructured":"Jiang T, Yan Y, Zhou K, Su C, Ren S, Li N, et al. Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. NPJ Precis Oncol. 2021;5:6. https:\/\/doi.org\/10.1038\/s41698-021-00151-w.","journal-title":"NPJ Precis Oncol"},{"key":"251_CR103","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/path.4583","volume":"237","author":"JM Saunus","year":"2015","unstructured":"Saunus JM, Quinn MC, Patch AM, Pearson JV, Bailey PJ, Nones K, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol. 2015;237:363\u201378. https:\/\/doi.org\/10.1002\/path.4583.","journal-title":"J Pathol"},{"key":"251_CR104","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","volume":"12","author":"AK Biswas","year":"2022","unstructured":"Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, et al. Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov. 2022;12:1002\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0910.","journal-title":"Cancer Discov"},{"key":"251_CR105","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jtho.2023.09.276","volume":"19","author":"X Wang","year":"2024","unstructured":"Wang X, Bai H, Zhang J, Wang Z, Duan J, Cai H, et al. Genetic intratumor heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer. J Thorac Oncol. 2024;19:252\u201372. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.276.","journal-title":"J Thorac Oncol"},{"key":"251_CR106","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-019-1092-4","volume":"38","author":"C Wei","year":"2019","unstructured":"Wei C, Dong X, Lu H, Tong F, Chen L, Zhang R, et al. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K\/AKT\/MYC pathway. J Exp Clin Cancer Res. 2019;38:95. https:\/\/doi.org\/10.1186\/s13046-019-1092-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"251_CR107","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12951-024-02414-7","volume":"22","author":"J Jiang","year":"2024","unstructured":"Jiang J, Lu Y, Chu J, Zhang X, Xu C, Liu S, et al. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases. J Nanobiotechnology. 2024;22:159. https:\/\/doi.org\/10.1186\/s12951-024-02414-7.","journal-title":"J Nanobiotechnology"},{"key":"251_CR108","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285. https:\/\/doi.org\/10.1038\/s41467-020-16164-1.","journal-title":"Nat Commun"},{"key":"251_CR109","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/neuonc\/noad017","volume":"25","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Y, Chang M, Wang Y, Liu P, Wu J, et al. Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma. Neuro Oncol. 2023;25:1262\u201374. https:\/\/doi.org\/10.1093\/neuonc\/noad017.","journal-title":"Neuro Oncol"},{"key":"251_CR110","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","volume":"185","author":"H Gonzalez","year":"2022","unstructured":"Gonzalez H, Mei W, Robles I, Hagerling C, Allen BM, Hauge Okholm TL, et al. Cellular architecture of human brain metastases. Cell. 2022;185:729-45 e20. https:\/\/doi.org\/10.1016\/j.cell.2021.12.043.","journal-title":"Cell"},{"key":"251_CR111","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell. 2020;181:1626-42 e20. https:\/\/doi.org\/10.1016\/j.cell.2020.04.055.","journal-title":"Cell"},{"key":"251_CR112","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181:1643-60 e17. https:\/\/doi.org\/10.1016\/j.cell.2020.05.007.","journal-title":"Cell"},{"key":"251_CR113","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023;614:555\u201363. https:\/\/doi.org\/10.1038\/s41586-022-05680-3.","journal-title":"Nature"},{"key":"251_CR114","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s42003-023-05124-2","volume":"6","author":"Q Song","year":"2023","unstructured":"Song Q, Ruiz J, Xing F, Lo HW, Craddock L, Pullikuth AK, et al. Single-cell sequencing reveals the landscape of the human brain metastatic microenvironment. Commun Biol. 2023;6:760. https:\/\/doi.org\/10.1038\/s42003-023-05124-2.","journal-title":"Commun Biol"},{"key":"251_CR115","doi-asserted-by":"publisher","first-page":"112804","DOI":"10.1016\/j.intimp.2024.112804","volume":"140","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Hu F, Chi Q. Single-cell RNA sequencing and spatial transcriptome reveal potential molecular mechanisms of lung cancer brain metastasis. Int Immunopharmacol. 2024;140:112804. https:\/\/doi.org\/10.1016\/j.intimp.2024.112804.","journal-title":"Int Immunopharmacol"},{"key":"251_CR116","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Abdo R, Iosef C, Kaneko T, Cecchini M, Han VK, et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat Commun. 2022;13:5983. https:\/\/doi.org\/10.1038\/s41467-022-33365-y.","journal-title":"Nat Commun"},{"key":"251_CR117","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cncr.20058","volume":"100","author":"FG Barker 2nd","year":"2004","unstructured":"Barker FG 2nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100:999\u20131007. https:\/\/doi.org\/10.1002\/cncr.20058.","journal-title":"Cancer"},{"key":"251_CR118","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3332\/ecancer.2013.308","volume":"7","author":"MA Hatiboglu","year":"2013","unstructured":"Hatiboglu MA, Wildrick DM, Sawaya R. The role of surgical resection in patients with brain metastases. Ecancermedicalscience. 2013;7:308. https:\/\/doi.org\/10.3332\/ecancer.2013.308.","journal-title":"Ecancermedicalscience"},{"key":"251_CR119","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/s0090-3019(02)00753-x","volume":"58","author":"H Takeshima","year":"2002","unstructured":"Takeshima H, Kuratsu J, Nishi T, Ushio Y. Prognostic factors in patients who survived more than 10 years after undergoing surgery for metastatic brain tumors: report of 5 cases and review of the literature. Surg Neurol. 2002;58:118\u201323. https:\/\/doi.org\/10.1016\/s0090-3019(02)00753-x. discussion 23.","journal-title":"Surg Neurol"},{"key":"251_CR120","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00595-014-0895-3","volume":"44","author":"T Kanou","year":"2014","unstructured":"Kanou T, Okami J, Tokunaga T, Fujiwara A, Ishida D, Kuno H, et al. Prognosis associated with surgery for non-small cell lung cancer and synchronous brain metastasis. Surg Today. 2014;44:1321\u20137. https:\/\/doi.org\/10.1007\/s00595-014-0895-3.","journal-title":"Surg Today"},{"key":"251_CR121","doi-asserted-by":"publisher","first-page":"e0253601","DOI":"10.1371\/journal.pone.0253601","volume":"16","author":"J Fuchs","year":"2021","unstructured":"Fuchs J, Fruh M, Papachristofilou A, Bubendorf L, Hauptle P, Jost L, et al. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: a retrospective multicenter study. PLoS ONE. 2021;16:e0253601. https:\/\/doi.org\/10.1371\/journal.pone.0253601.","journal-title":"PLoS ONE"},{"key":"251_CR122","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-017-2510-0","volume":"134","author":"D Bernhardt","year":"2017","unstructured":"Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hoerner-Rieber J, Konig L, et al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neurooncol. 2017;134:205\u201312. https:\/\/doi.org\/10.1007\/s11060-017-2510-0.","journal-title":"J Neurooncol"},{"key":"251_CR123","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.21037\/jtd-2019-rbmlc-06","volume":"13","author":"B Sas-Korczynska","year":"2021","unstructured":"Sas-Korczynska B, Rucinska M. WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view. J Thorac Dis. 2021;13:3246\u201357. https:\/\/doi.org\/10.21037\/jtd-2019-rbmlc-06.","journal-title":"J Thorac Dis"},{"key":"251_CR124","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","volume":"15","author":"J Zhen","year":"2020","unstructured":"Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, et al. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol. 2020;15:185. https:\/\/doi.org\/10.1186\/s13014-020-01627-y.","journal-title":"Radiat Oncol"},{"key":"251_CR125","doi-asserted-by":"publisher","first-page":"144","DOI":"10.12659\/MSM.892405","volume":"21","author":"H Qin","year":"2015","unstructured":"Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Med Sci Monit. 2015;21:144\u201352. https:\/\/doi.org\/10.12659\/MSM.892405.","journal-title":"Med Sci Monit"},{"key":"251_CR126","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-015-1103-6","volume":"15","author":"S Yomo","year":"2015","unstructured":"Yomo S, Hayashi M. Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients. BMC Cancer. 2015;15:95. https:\/\/doi.org\/10.1186\/s12885-015-1103-6.","journal-title":"BMC Cancer"},{"key":"251_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2021.06.026","volume":"162","author":"GA Viani","year":"2021","unstructured":"Viani GA, Gouveia AG, Louie AV, Moraes FY. Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: a meta-analysis. Radiother Oncol. 2021;162:45\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2021.06.026.","journal-title":"Radiother Oncol"},{"key":"251_CR128","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.30009","volume":"122","author":"LM Halasz","year":"2016","unstructured":"Halasz LM, Uno H, Hughes M, D\u2019Amico T, Dexter EU, Edge SB, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016;122:2091\u2013100. https:\/\/doi.org\/10.1002\/cncr.30009.","journal-title":"Cancer"},{"key":"251_CR129","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctro.2019.12.001","volume":"21","author":"J Nikitas","year":"2020","unstructured":"Nikitas J, Roach M, Robinson C, Bradley J, Huang J, Perkins S, et al. Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 2020;21:32\u20135. https:\/\/doi.org\/10.1016\/j.ctro.2019.12.001.","journal-title":"Clin Transl Radiat Oncol"},{"key":"251_CR130","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00701-012-1520-0","volume":"155","author":"K Nakazaki","year":"2013","unstructured":"Nakazaki K, Higuchi Y, Nagano O, Serizawa T. Efficacy and limitations of salvage gamma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy. Acta Neurochir (Wien). 2013;155:107\u201313. https:\/\/doi.org\/10.1007\/s00701-012-1520-0. discussion 13-4.","journal-title":"Acta Neurochir (Wien)"},{"key":"251_CR131","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.ijrobp.2011.11.059","volume":"83","author":"S Harris","year":"2012","unstructured":"Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:e53-9. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.11.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"251_CR132","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(04)16250-8.","journal-title":"Lancet"},{"key":"251_CR133","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32:1332\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.016.","journal-title":"Ann Oncol"},{"key":"251_CR134","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437\u201349. https:\/\/doi.org\/10.1007\/s10545-013-9608-0.","journal-title":"J Inherit Metab Dis"},{"key":"251_CR135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99:21\u201378. https:\/\/doi.org\/10.1152\/physrev.00050.2017.","journal-title":"Physiol Rev"},{"key":"251_CR136","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13\u201325. https:\/\/doi.org\/10.1016\/j.nbd.2009.07.030.","journal-title":"Neurobiol Dis"},{"key":"251_CR137","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature25739","volume":"554","author":"M Vanlandewijck","year":"2018","unstructured":"Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475\u201380. https:\/\/doi.org\/10.1038\/nature25739.","journal-title":"Nature"},{"key":"251_CR138","doi-asserted-by":"publisher","first-page":"606300","DOI":"10.3389\/fonc.2020.606300","volume":"10","author":"Y Kang","year":"2020","unstructured":"Kang Y, Jin Y, Li Q, Yuan X. Advances in Lung cancer driver genes associated with brain metastasis. Front Oncol. 2020;10:606300. https:\/\/doi.org\/10.3389\/fonc.2020.606300.","journal-title":"Front Oncol"},{"key":"251_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_352320","volume":"42","author":"C Alvarez-Breckenridge","year":"2022","unstructured":"Alvarez-Breckenridge C, Remon J, Pina Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, et al. Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients. Am Soc Clin Oncol Educ Book. 2022;42:1\u201319. https:\/\/doi.org\/10.1200\/EDBK_352320.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"251_CR140","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","volume":"82","author":"T Iuchi","year":"2013","unstructured":"Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82:282\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2013.08.016.","journal-title":"Lung Cancer"},{"key":"251_CR141","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399.","journal-title":"Clin Cancer Res"},{"key":"251_CR142","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","volume":"33","author":"DB Costa","year":"2015","unstructured":"Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.59.0539.","journal-title":"J Clin Oncol"},{"key":"251_CR143","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.18632\/oncotarget.23616","volume":"9","author":"YW Sun","year":"2018","unstructured":"Sun YW, Xu J, Zhou J, Liu WJ. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 2018;9:5459\u201372. https:\/\/doi.org\/10.18632\/oncotarget.23616.","journal-title":"Oncotarget"},{"key":"251_CR144","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.71.5904.","journal-title":"J Clin Oncol"},{"key":"251_CR145","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.21.02278","volume":"40","author":"BJ Solomon","year":"2022","unstructured":"Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, et al. Post Hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40:3593\u2013602. https:\/\/doi.org\/10.1200\/JCO.21.02278.","journal-title":"J Clin Oncol"},{"key":"251_CR146","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00280-019-03902-6","volume":"84","author":"A Roys","year":"2019","unstructured":"Roys A, Chang X, Liu Y, Xu X, Wu Y, Zuo D. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother Pharmacol. 2019;84:679\u201388. https:\/\/doi.org\/10.1007\/s00280-019-03902-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"251_CR147","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","volume":"28","author":"JK Sabari","year":"2022","unstructured":"Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, et al. Activity of Adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin Cancer Res. 2022;28:3318\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0383.","journal-title":"Clin Cancer Res"},{"key":"251_CR148","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","volume":"10","author":"M Santarpia","year":"2021","unstructured":"Santarpia M, Massafra M, Gebbia V, D\u2019Aquino A, Garipoli C, Altavilla G, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl Lung Cancer Res. 2021;10:1536\u201356. https:\/\/doi.org\/10.21037\/tlcr-20-1113.","journal-title":"Transl Lung Cancer Res"},{"key":"251_CR149","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2174\/187152009788451879","volume":"9","author":"J Ansari","year":"2009","unstructured":"Ansari J, Palmer DH, Rea DW, Hussain SA. Role of tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2009;9:569\u201375. https:\/\/doi.org\/10.2174\/187152009788451879.","journal-title":"Anticancer Agents Med Chem"},{"key":"251_CR150","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1200\/EDBK_100006","volume":"35","author":"VA Venur","year":"2016","unstructured":"Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book. 2016;35:e123-30. https:\/\/doi.org\/10.1200\/EDBK_100006.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"251_CR151","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"key":"251_CR152","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"key":"251_CR153","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021;23:1447\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noab101.","journal-title":"Neuro Oncol"},{"key":"251_CR154","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/pharmaceutics13091446","volume":"13","author":"E Angeli","year":"2021","unstructured":"Angeli E, Bousquet G. Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier. Pharmaceutics. 2021;13:1446. https:\/\/doi.org\/10.3390\/pharmaceutics13091446.","journal-title":"Pharmaceutics"},{"key":"251_CR155","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","volume":"5","author":"MJ Ahn","year":"2017","unstructured":"Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5:891\u2013902. https:\/\/doi.org\/10.1016\/S2213-2600(17)30378-8.","journal-title":"Lancet Respir Med"},{"key":"251_CR156","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S1470-2045(17)30342-X","volume":"18","author":"M Das","year":"2017","unstructured":"Das M. Brigatinib effective in ALK-positive non-small-cell lung cancer. Lancet Oncol. 2017;18:e310. https:\/\/doi.org\/10.1016\/S1470-2045(17)30342-X.","journal-title":"Lancet Oncol"},{"key":"251_CR157","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11:354\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(22)00437-4.","journal-title":"Lancet Respir Med"},{"key":"251_CR158","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in alk inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091\u2013108. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.035.","journal-title":"J Thorac Oncol"},{"key":"251_CR159","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2027187.","journal-title":"N Engl J Med"},{"key":"251_CR160","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","volume":"32","author":"E Felip","year":"2021","unstructured":"Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32:620\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.012.","journal-title":"Ann Oncol"},{"key":"251_CR161","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/ijms21041416","volume":"21","author":"AC Tan","year":"2020","unstructured":"Tan AC, Itchins M, Khasraw M. Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci. 2020;21:1416. https:\/\/doi.org\/10.3390\/ijms21041416.","journal-title":"Int J Mol Sci"},{"key":"251_CR162","doi-asserted-by":"publisher","first-page":"PR02","DOI":"10.1158\/1535-7163.Targ-19-pr02","volume":"18","author":"AM Schram","year":"2019","unstructured":"Schram AM, O\u2019Reilly EM, Somwar R, Benayed R, Shameem S, Chauhan T, et al. Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2\/3 antibody therapy, in NRG1 fusion-positive cancers. Mol Cancer Ther. 2019;18:PR02. https:\/\/doi.org\/10.1158\/1535-7163.Targ-19-pr02.","journal-title":"Mol Cancer Ther"},{"key":"251_CR163","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2017.00193","volume":"8","author":"KA Bohn","year":"2017","unstructured":"Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017;8:193. https:\/\/doi.org\/10.3389\/fphar.2017.00193.","journal-title":"Front Pharmacol"},{"key":"251_CR164","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10585-020-10055-x","volume":"37","author":"B Kovalchuk","year":"2020","unstructured":"Kovalchuk B, Berghoff AS, Karreman MA, Frey K, Piechutta M, Fischer M, et al. Nintedanib and a bi-specific anti-VEGF\/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells. Clin Exp Metastasis. 2020;37:637\u201348. https:\/\/doi.org\/10.1007\/s10585-020-10055-x.","journal-title":"Clin Exp Metastasis"},{"key":"251_CR165","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s43018-021-00198-5","volume":"2","author":"PK Brastianos","year":"2021","unstructured":"Brastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021;2:498\u2013502. https:\/\/doi.org\/10.1038\/s43018-021-00198-5.","journal-title":"Nat Cancer"},{"key":"251_CR166","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11060-014-1369-6","volume":"117","author":"PF Peddi","year":"2014","unstructured":"Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol. 2014;117:7\u201313. https:\/\/doi.org\/10.1007\/s11060-014-1369-6.","journal-title":"J Neurooncol"},{"key":"251_CR167","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378. https:\/\/doi.org\/10.1056\/NEJMra1514296.","journal-title":"N Engl J Med"},{"key":"251_CR168","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1200\/EDBK_100005","volume":"35","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116-22. https:\/\/doi.org\/10.1200\/EDBK_100005.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"251_CR169","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"key":"251_CR170","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6.","journal-title":"Lancet Oncol"},{"key":"251_CR171","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22:1692\u2013704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3.","journal-title":"Lancet Oncol"},{"key":"251_CR172","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14:1244\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009.","journal-title":"J Thorac Oncol"},{"key":"251_CR173","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895\u2013903. https:\/\/doi.org\/10.1016\/S1470-2045(17)30380-7.","journal-title":"Lancet Oncol"},{"key":"251_CR174","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"251_CR175","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cllc.2021.06.009","volume":"23","author":"Y Yang","year":"2022","unstructured":"Yang Y, Deng L, Yang Y, Zhang T, Wu Y, Wang L, et al. Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis. Clin Lung Cancer. 2022;23:95\u2013107. https:\/\/doi.org\/10.1016\/j.cllc.2021.06.009.","journal-title":"Clin Lung Cancer"},{"key":"251_CR176","doi-asserted-by":"publisher","first-page":"669398","DOI":"10.3389\/fimmu.2021.669398","volume":"12","author":"H Hu","year":"2021","unstructured":"Hu H, Xu ZY, Zhu Q, Liu X, Jiang SC, Zheng JH. Brain metastases status and immunotherapy efficacy in advanced lung cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:669398. https:\/\/doi.org\/10.3389\/fimmu.2021.669398.","journal-title":"Front Immunol"},{"key":"251_CR177","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(20)30207-2","volume":"21","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Tomasini P. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol. 2020;21:607\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(20)30207-2.","journal-title":"Lancet Oncol"},{"key":"251_CR178","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00432-022-04121-y","volume":"149","author":"J Chang","year":"2023","unstructured":"Chang J, Jing X, Hua Y, Geng K, Li R, Lu S, et al. Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases. J Cancer Res Clin Oncol. 2023;149:1825\u201333. https:\/\/doi.org\/10.1007\/s00432-022-04121-y.","journal-title":"J Cancer Res Clin Oncol"},{"key":"251_CR179","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jmri.26171","volume":"48","author":"SC Thust","year":"2018","unstructured":"Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018;48:571\u201389. https:\/\/doi.org\/10.1002\/jmri.26171.","journal-title":"J Magn Reson Imaging"},{"key":"251_CR180","doi-asserted-by":"publisher","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119491.","journal-title":"Biomaterials"},{"key":"251_CR181","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20:362\u201383. https:\/\/doi.org\/10.1038\/s41573-021-00139-y.","journal-title":"Nat Rev Drug Discov"},{"key":"251_CR182","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res. 2020;26:2789\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3258.","journal-title":"Clin Cancer Res"},{"key":"251_CR183","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2017.04.033","volume":"258","author":"S Quader","year":"2017","unstructured":"Quader S, Liu X, Chen Y, Mi P, Chida T, Ishii T, et al. cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors. J Control Release. 2017;258:56\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.033.","journal-title":"J Control Release"},{"key":"251_CR184","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1385\/MB:30:1:057","volume":"30","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005;30:57\u201370. https:\/\/doi.org\/10.1385\/MB:30:1:057.","journal-title":"Mol Biotechnol"},{"key":"251_CR185","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.apsb.2014.03.001","volume":"4","author":"X Wei","year":"2014","unstructured":"Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B. 2014;4:193\u2013201. https:\/\/doi.org\/10.1016\/j.apsb.2014.03.001.","journal-title":"Acta Pharm Sin B"},{"key":"251_CR186","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2014.09.018","volume":"196","author":"CP Foley","year":"2014","unstructured":"Foley CP, Rubin DG, Santillan A, Sondhi D, Dyke JP, Crystal RG, et al. Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J Control Release. 2014;196:71\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2014.09.018.","journal-title":"J Control Release"},{"key":"251_CR187","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2010.9.JNS101223","volume":"114","author":"JA Boockvar","year":"2011","unstructured":"Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011;114:624\u201332. https:\/\/doi.org\/10.3171\/2010.9.JNS101223.","journal-title":"J Neurosurg"},{"key":"251_CR188","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijpharm.2012.06.025","volume":"436","author":"D Allhenn","year":"2012","unstructured":"Allhenn D, Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436:299\u2013310. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.06.025.","journal-title":"Int J Pharm"},{"key":"251_CR189","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","volume":"91","author":"RH Bobo","year":"1994","unstructured":"Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076\u201380. https:\/\/doi.org\/10.1073\/pnas.91.6.2076.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"251_CR190","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jneumeth.2009.12.008","volume":"187","author":"D Yin","year":"2010","unstructured":"Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods. 2010;187:46\u201351. https:\/\/doi.org\/10.1016\/j.jneumeth.2009.12.008.","journal-title":"J Neurosci Methods"},{"key":"251_CR191","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/neuonc\/nou026","volume":"16","author":"AM Sonabend","year":"2014","unstructured":"Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, et al. Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol. 2014;16:1210\u20139. https:\/\/doi.org\/10.1093\/neuonc\/nou026.","journal-title":"Neuro Oncol"},{"key":"251_CR192","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jneumeth.2010.01.002","volume":"187","author":"GW Astary","year":"2010","unstructured":"Astary GW, Kantorovich S, Carney PR, Mareci TH, Sarntinoranont M. Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo. J Neurosci Methods. 2010;187:129\u201337. https:\/\/doi.org\/10.1016\/j.jneumeth.2010.01.002.","journal-title":"J Neurosci Methods"},{"key":"251_CR193","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1227\/01.neu.0000159649.71890.30","volume":"56","author":"SJ Patel","year":"2005","unstructured":"Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery. 2005;56:1243\u201352. https:\/\/doi.org\/10.1227\/01.neu.0000159649.71890.30. discussion 52-3.","journal-title":"Neurosurgery"},{"key":"251_CR194","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.biomaterials.2009.01.003","volume":"30","author":"E Allard","year":"2009","unstructured":"Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30:2302\u201318. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.01.003.","journal-title":"Biomaterials"},{"key":"251_CR195","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nano.2013.07.003","volume":"10","author":"GM Bernal","year":"2014","unstructured":"Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2014;10:149\u201357. https:\/\/doi.org\/10.1016\/j.nano.2013.07.003.","journal-title":"Nanomedicine"},{"key":"251_CR196","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0090-3019(00)00211-1","volume":"53","author":"HH Engelhard","year":"2000","unstructured":"Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol. 2000;53:458\u201364. https:\/\/doi.org\/10.1016\/s0090-3019(00)00211-1.","journal-title":"Surg Neurol"},{"key":"251_CR197","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/jpet.119.258152","volume":"370","author":"Z Wang","year":"2019","unstructured":"Wang Z, Xiong G, Tsang WC, Schatzlein AG, Uchegbu IF. Nose-to-brain delivery. J Pharmacol Exp Ther. 2019;370:593\u2013601. https:\/\/doi.org\/10.1124\/jpet.119.258152.","journal-title":"J Pharmacol Exp Ther"},{"key":"251_CR198","doi-asserted-by":"publisher","first-page":"e000634","DOI":"10.1136\/esmoopen-2019-000634","volume":"5","author":"SY Kim","year":"2020","unstructured":"Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open. 2020;5:e000634. https:\/\/doi.org\/10.1136\/esmoopen-2019-000634.","journal-title":"ESMO Open"},{"key":"251_CR199","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149:8131\u201341. https:\/\/doi.org\/10.1007\/s00432-023-04737-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"251_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1\u201312. https:\/\/doi.org\/10.1038\/s41423-019-0306-1.","journal-title":"Cell Mol Immunol"},{"key":"251_CR201","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/imm.13520","volume":"168","author":"J Wang","year":"2023","unstructured":"Wang J, Gong R, Zhao C, Lei K, Sun X, Ren H. Human FOXP3 and tumour microenvironment. Immunology. 2023;168:248\u201355. https:\/\/doi.org\/10.1111\/imm.13520.","journal-title":"Immunology"},{"key":"251_CR202","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"251_CR203","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21:1639\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2339.","journal-title":"Clin Cancer Res"},{"key":"251_CR204","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70:5213\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0118.","journal-title":"Cancer Res"},{"key":"251_CR205","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236","volume":"123","author":"DA Knight","year":"2013","unstructured":"Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013;123:1371\u201381. https:\/\/doi.org\/10.1172\/JCI66236.","journal-title":"J Clin Invest"},{"key":"251_CR206","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/2326-6066.CIR-14-0074","volume":"2","author":"SM Steinberg","year":"2014","unstructured":"Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res. 2014;2:1044\u201350. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0074.","journal-title":"Cancer Immunol Res"},{"key":"251_CR207","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4691.","journal-title":"Sci Transl Med"},{"key":"251_CR208","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0915.","journal-title":"Cancer Discov"},{"key":"251_CR209","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25:2972-80 e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.054.","journal-title":"Cell Rep"},{"key":"251_CR210","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003.","journal-title":"Cancer Res"},{"key":"251_CR211","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1020.","journal-title":"Cancer Discov"},{"key":"251_CR212","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2326-6066.CIR-18-0071","volume":"7","author":"L Ding","year":"2019","unstructured":"Ding L, Chen X, Xu X, Qian Y, Liang G, Yao F, et al. PARP1 suppresses the transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunol Res. 2019;7:136\u201349. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0071.","journal-title":"Cancer Immunol Res"},{"key":"251_CR213","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9:1853. https:\/\/doi.org\/10.1038\/s41598-019-38534-6.","journal-title":"Sci Rep"},{"key":"251_CR214","doi-asserted-by":"publisher","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109:djw199. https:\/\/doi.org\/10.1093\/jnci\/djw199.","journal-title":"J Natl Cancer Inst"},{"key":"251_CR215","doi-asserted-by":"publisher","unstructured":"Masuda C, Onishi S, Yorozu K, Kurasawa M, Morinaga M, Wakita D, et al. PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model. Clin Exp Metastasis. 2024. https:\/\/doi.org\/10.1007\/s10585-024-10309-y.","DOI":"10.1007\/s10585-024-10309-y"},{"key":"251_CR216","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ccell.2024.09.012","volume":"42","author":"M Fu","year":"2024","unstructured":"Fu M, Zhao J, Zhang L, Sheng Z, Li X, Qiu F, et al. Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade. Cancer Cell. 2024;42:1882-97 e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.012.","journal-title":"Cancer Cell"},{"key":"251_CR217","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s43018-021-00183-y","volume":"2","author":"GB Ferraro","year":"2021","unstructured":"Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2:414\u201328. https:\/\/doi.org\/10.1038\/s43018-021-00183-y.","journal-title":"Nat Cancer"},{"key":"251_CR218","doi-asserted-by":"publisher","first-page":"e192553","DOI":"10.1001\/jamaoncol.2019.2553","volume":"5","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Barron F, Padilla MS, Aviles-Salas A, Ramirez-Tirado LA, Arguelles Jimenez MJ, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:e192553. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2553.","journal-title":"JAMA Oncol"},{"key":"251_CR219","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1073\/pnas.2009620118","volume":"118","author":"KM Dalton","year":"2021","unstructured":"Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, et al. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. Proc Natl Acad Sci U S A. 2021;118:20-e2009620118. https:\/\/doi.org\/10.1073\/pnas.2009620118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"251_CR220","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 2019;9:628\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1489.","journal-title":"Cancer Discov"},{"key":"251_CR221","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cmet.2012.05.001","volume":"15","author":"I Marin-Valencia","year":"2012","unstructured":"Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15:827\u201337. https:\/\/doi.org\/10.1016\/j.cmet.2012.05.001.","journal-title":"Cell Metab"},{"key":"251_CR222","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","volume":"11","author":"S Bonnet","year":"2007","unstructured":"Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37\u201351. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.020.","journal-title":"Cancer Cell"},{"key":"251_CR223","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1542\/peds.2005-1226","volume":"117","author":"PW Stacpoole","year":"2006","unstructured":"Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117:1519\u201331. https:\/\/doi.org\/10.1542\/peds.2005-1226.","journal-title":"Pediatrics"},{"key":"251_CR224","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.eururo.2015.09.014","volume":"69","author":"A Kinnaird","year":"2016","unstructured":"Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, et al. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur Urol. 2016;69:734\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2015.09.014.","journal-title":"Eur Urol"},{"key":"251_CR225","doi-asserted-by":"publisher","first-page":"e000262","DOI":"10.1136\/esmoopen-2017-000262","volume":"3","author":"M Preusser","year":"2018","unstructured":"Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262. https:\/\/doi.org\/10.1136\/esmoopen-2017-000262.","journal-title":"ESMO Open"},{"key":"251_CR226","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.lungcan.2013.05.011","volume":"81","author":"J Bauml","year":"2013","unstructured":"Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013;81:347\u201353. https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.011.","journal-title":"Lung Cancer"},{"key":"251_CR227","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154\u201362. https:\/\/doi.org\/10.1097\/JTO.0000000000000033.","journal-title":"J Thorac Oncol"},{"key":"251_CR228","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136. https:\/\/doi.org\/10.1038\/nature05945.","journal-title":"Nature"},{"key":"251_CR229","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.lungcan.2013.01.019","volume":"80","author":"M Preusser","year":"2013","unstructured":"Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer. 2013;80:278\u201383. https:\/\/doi.org\/10.1016\/j.lungcan.2013.01.019.","journal-title":"Lung Cancer"},{"key":"251_CR230","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409\u201316. https:\/\/doi.org\/10.1093\/annonc\/mdy121.","journal-title":"Ann Oncol"},{"key":"251_CR231","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1.","journal-title":"Lancet Oncol"},{"key":"251_CR232","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379:2027\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1810171.","journal-title":"N Engl J Med"},{"key":"251_CR233","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.cllc.2014.06.004","volume":"15","author":"R Chiari","year":"2014","unstructured":"Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. Clin Lung Cancer. 2014;15:470\u20134. https:\/\/doi.org\/10.1016\/j.cllc.2014.06.004.","journal-title":"Clin Lung Cancer"},{"key":"251_CR234","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11060-014-1446-x","volume":"118","author":"M Preusser","year":"2014","unstructured":"Preusser M, Streubel B, Birner P. ROS1 translocations and amplifications in lung cancer brain metastases. J Neurooncol. 2014;118:425\u20136. https:\/\/doi.org\/10.1007\/s11060-014-1446-x.","journal-title":"J Neurooncol"},{"key":"251_CR235","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41598-021-81832-1","volume":"11","author":"AM Baschnagel","year":"2021","unstructured":"Baschnagel AM, Kaushik S, Durmaz A, Goldstein S, Ong IM, Abel L, et al. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Sci Rep. 2021;11:2520. https:\/\/doi.org\/10.1038\/s41598-021-81832-1.","journal-title":"Sci Rep"},{"key":"251_CR236","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lungcan.2021.11.020","volume":"163","author":"M Friese-Hamim","year":"2022","unstructured":"Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, et al. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases. Lung Cancer. 2022;163:77\u201386. https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.020.","journal-title":"Lung Cancer"},{"key":"251_CR237","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232\u201350. https:\/\/doi.org\/10.1038\/s43018-022-00337-6.","journal-title":"Nat Cancer"},{"key":"251_CR238","doi-asserted-by":"publisher","first-page":"100623","DOI":"10.1016\/j.xcrm.2022.100623","volume":"3","author":"CC Faria","year":"2022","unstructured":"Faria CC, Cascao R, Custodia C, Paisana E, Carvalho T, Pereira P, et al. Patient-derived models of brain metastases recapitulate human disseminated disease. Cell Rep Med. 2022;3:100623. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100623.","journal-title":"Cell Rep Med"},{"key":"251_CR239","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1038\/s41467-021-25177-3","volume":"12","author":"H Sun","year":"2021","unstructured":"Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021;12:5086. https:\/\/doi.org\/10.1038\/s41467-021-25177-3.","journal-title":"Nat Commun"},{"key":"251_CR240","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal E, Rodriguez-Abreu D, Simo M, Massuti B, Juan O, Huidobro G, et al. Phase II trial of Atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05). J Clin Oncol. 2023;41:4478\u201385. https:\/\/doi.org\/10.1200\/JCO.22.02561.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00251-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:16:51Z","timestamp":1740475011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00251-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":240,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00251-0","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors state that there is no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}